Summary:
Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a PT desk review performed on 03/11/2021, based on review of CASPER report 155D and graded reports from American Proficiency Institute (API) the laboratory failed to successfully participate in proficiency testing for the following regulated hematology anlytes: red blood cell (RBC), hematocrit (HCT), hemoglobin (Hgb), and white blood cell (WBC), for two of three consecutive proficiency testing events reviewed (2020, Events 1 and 2). See D2121 and D2130. D2121 HEMATOLOGY CFR(s): 493.851(a) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: During a proficiency testing desk review performed on 03/11/2021, based on review of the CASPER report 155D and laboratory proficiency testing records (graded report from API), it was determined that the laboratory failed to attain a score of at least 80 percent in proficiency testing for the specialty of hematology, the analytes RBC, HCT, HGB, and WBC for two consecutive proficiency testing events (2020, Events 1 and 2). The findings include: 1. Review of CASPER report 155D revealed the following Plt proficiency scores for your laboratory for 2020 Event 1: a. RBC: 0% b. HCT: 0% c. HGB: 0% d. WBC: 0% Review of CASPER report 155D revealed the following Plt proficiency scores for your laboratory for 2020 Event 2: a. RBC: 0% b. HCT: 0% c. HGB: 0% d. WBC: 0% 2. The scores were confirmed upon review of the graded API reports. Scores less than 80% for these analytes indicate failure or unsatisfactory performance. A failure of the analytes for two consecutive or two out of three testing events is scored as unsuccessful. A failure of the analyte for three consecutive or three out of four/five events is scored as a repeat unsuccessful. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: During the desk review performed on 03/11/2021, based on review of CASPER report 155D and graded API results, it was determined that the laboratory failed to achieve satisfactory performance for the analyte RBC, HCT, HGB, and WBC in two of three consecutive testing events (2020, Events 1 and 2) resulting in unsuccessful proficiency testing performance. See D2121. -- 2 of 2 --